Severe fatigue and memory impairment are associated with lower serum level of anti-SARS-CoV-2 antibodies in patients with Post-COVID symptomsShow others and affiliations
2021 (English)In: Journal of Clinical Medicine, E-ISSN 2077-0383, Vol. 10, no 19, p. 4337-4337Article in journal (Refereed) Published
Abstract [en]
Background: Post-COVID manifestation is defined as persistent symptoms or long-term complications beyond 4 weeks from disease onset. Fatigue and memory impairment are common post-COVID symptoms. We aimed to explore associations between the timeline and severity of post-COVID fatigue and anti-SARS-CoV-2 antibodies.
Methods: Fatigue and memory impairment were assessed in a total of 101 post-COVID subjects using the Chalder fatigue scale (CFQ-11) and a visual analogue scale. Using the bimodal scoring system generated from CFQ-11, a score ≥4 was defined as severe fatigue. Serum anti-SARS-CoV-2 spike (anti-S-Ig) and nucleocapsid (anti-NC-Ig) antibodies were examined at two time points: 4-12 weeks after onset of symptoms, and beyond 12 weeks.
Results: The serum level of anti-S-Ig was significantly higher in patients with non-severe fatigue compared to those with severe fatigue at 4-12 weeks (p = 0.006) and beyond 12 weeks (p = 0.016). The serum level of anti-NC-Ig remained high in patients with non-severe fatigue at both time points. In contrast, anti-NC-Ig decreased significantly in severe fatigue cases regardless of the elapsed time (4-12 weeks: p = 0.024; beyond 12 weeks: p = 0.005). The incidence of memory impairment was significantly correlated with lower anti-S-Ig levels (-0.359, p < 0.001).
Conclusion: The systemic immune response reflected by antibodies to SARS-CoV-2 is strongly correlated with the severity of post-COVID fatigue.
Place, publisher, year, edition, pages
MDPI, 2021. Vol. 10, no 19, p. 4337-4337
Keywords [en]
anti-SARS-CoV-2 nucleocapsid Ig, anti-SARS-CoV-2 spike Ig, memory impairment, post-COVID fatigue
National Category
Neurology
Identifiers
URN: urn:nbn:se:oru:diva-113730DOI: 10.3390/jcm10194337ISI: 000708229900001PubMedID: 34640355Scopus ID: 2-s2.0-85115417422OAI: oai:DiVA.org:oru-113730DiVA, id: diva2:1859154
2024-05-212024-05-212024-05-21Bibliographically approved